- Home
- INZY vs ARAY Comparison
INZY vs ARAY Comparison
Compare INZY & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- ARAY
- Stock Information
- Founded
- INZY 2015
- ARAY 1990
- Country
- INZY United States
- ARAY United States
- Employees
- INZY N/A
- ARAY N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- ARAY Medical/Dental Instruments
- Sector
- INZY Health Care
- ARAY Health Care
- Exchange
- INZY Nasdaq
- ARAY Nasdaq
- Market Cap
- INZY 188.2M
- ARAY 180.0M
- IPO Year
- INZY 2020
- ARAY 2007
- Fundamental
- Price
- INZY $2.00
- ARAY $2.14
- Analyst Decision
- INZY Strong Buy
- ARAY Strong Buy
- Analyst Count
- INZY 7
- ARAY 1
- Target Price
- INZY $16.43
- ARAY $9.00
- AVG Volume (30 Days)
- INZY 666.9K
- ARAY 603.0K
- Earning Date
- INZY 11-05-2024
- ARAY 01-29-2025
- Dividend Yield
- INZY N/A
- ARAY N/A
- EPS Growth
- INZY N/A
- ARAY N/A
- EPS
- INZY N/A
- ARAY N/A
- Revenue
- INZY N/A
- ARAY $444,204,000.00
- Revenue This Year
- INZY N/A
- ARAY $6.64
- Revenue Next Year
- INZY N/A
- ARAY $5.69
- P/E Ratio
- INZY N/A
- ARAY N/A
- Revenue Growth
- INZY N/A
- ARAY N/A
- 52 Week Low
- INZY $1.97
- ARAY $1.40
- 52 Week High
- INZY $7.80
- ARAY $2.99
- Technical
- Relative Strength Index (RSI)
- INZY 33.08
- ARAY 58.64
- Support Level
- INZY $2.68
- ARAY $1.76
- Resistance Level
- INZY $3.18
- ARAY $2.29
- Average True Range (ATR)
- INZY 0.23
- ARAY 0.13
- MACD
- INZY -0.01
- ARAY 0.03
- Stochastic Oscillator
- INZY 2.52
- ARAY 71.70
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.